Key result
Peripheral arterial disease is linked to significantly higher levels of multiple inflammatory biomarkers.
Case-Control (n=152)
Answers are grounded in this paper and cite their sources.
Previous research analyzed the level of plasma inflammatory markers in patients with coronary disease, but very few studies have evaluated these markers in patients with peripheral arterial disease (PAD). The objective of this study was to investigate the plasma levels of inflammatory markers in patients with PAD and in healthy controls. The following plasma levels of biomarkers were measured in 80 patients with PAD (mean age 68 ± 5 years) and in 72 healthy participants (mean age 67 ± 6 years): interleukin 6 (IL-6), tumor necrosis factor α (TNF-α), L-selectin (LS), neopterin (N), P-selectin (PS), E-selectin (ES), vascular cell adhesion molecule 1 (VCAM-1), intercellular adhesion molecule 1 (ICAM-1), and matrix metalloproteinase 2 (MMP-2), and 9 (MMP-9). Significantly higher levels of IL-6 (P < .001), TNF-α (P < .0001), ES (P < .0001), LS (P < .0001), PS (P < .0001), ICAM-1 (P < .001), VCAM-1 (P < .001), N (P < .001), MMP-2 (P < .001), and MMP-9 (P < .005) were found in the patients with PAD. Patients with PAD show a inflammation marker profile different from that of control participants. Reducing the high plasma levels of inflammatory markers could be a new therapeutic approach both for the prevention and the treatment of PAD.
No takes yet. Share an insight, caveat, or question.
Signorelli et al. (2016) conducted a case-control in Peripheral arterial disease (n=152). Peripheral arterial disease vs. Healthy controls was evaluated on Plasma levels of inflammatory biomarkers (IL-6, TNF-α, LS, N, PS, ES, VCAM-1, ICAM-1, MMP-2, MMP-9) (p=<.001). Patients with peripheral arterial disease had higher plasma levels of multiple inflammatory biomarkers, including IL-6 and TNF-α, compared to healthy controls.
Synapse has enriched 10 related papers. Consider them for comparative context: